Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
4
Virginia Commonwealth University
Richmond, Virginia, United States
Change in vascular function
Flow-mediated dilation will be used to measure vasodilation in the brachial artery
Time frame: Baseline and 6 weeks
Change in Skeletal Muscle Oxygenation
Near-infrared spectroscopy will be used to measure leg muscle oxygenation
Time frame: Baseline and 6 weeks
Change in oxidative stress
Blood draws will be taken to measure oxidative stress markers in the blood through electron paramagnetic resonance
Time frame: Baseline and 6 weeks
Change in arterial stiffness
Pulse wave velocity will be used to measure arterial stiffness.
Time frame: Baseline and 6 weeks
Change in microvascular function
Microvascular function will be assessed using laser dopler imaging
Time frame: Baseline and 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.